What is hypoglycemia in patients with well-controlled type 1 diabetes treated by subcutaneous insulin pump with use of the continuous glucose monitoring system?

Jennifer Lynn Larsen, Tim Ford, Elizabeth Lyden, Chris Colling, Lynn R Mack, James Lane

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Objective: To analyze 72-hour interstitial glucose concentrations measured by a glucose sensor in adult subjects. Methods: We compared glucose levels in 10 patients with type 1 diabetes mellitus (DM-1) and 10 normal control subjects with use of the Medtronic Continuous Glucose Monitoring System (CGMS). Hypoglycemic events identified by the CGMS, the patients, or both were compared in the patients with DM-1. In addition, the results between two glucose sensors placed at similar sites in the same subject were evaluated. Results: Hemoglobin A1c and mean glucose values were higher in the DM-1 group than in the control group (P<0.01), whereas time spent at glucose levels of less than 60, 60 to 79, and 121 to 150 mg/dL were similar between the two study groups. Time spent at glucose levels above 150 mg/dL was greater in the DM-1 group than in the control group (P<0.05). Of the 74 total hypoglycemic events in the patients with DM-1, the sensor and the patient recognized 14%, only the patient recognized 9% (confirmed by readings of <55 mg/dL on a glucose meter), and only the sensor detected 77%. Of note, 41% of the patient-identified symptomatic hypoglycemic events were missed by the CGMS. When one patient with DM-1 and one control subject wore two glucose sensors simultaneously, one and not the other sensor often identified "hypoglycemia," and the correlation was only fair to good by intraclass correlation analysis. Conclusion: Many asymptomatic "hypoglycemic events" identified by the CGMS may not be actual hypoglycemia. Hypoglycemia is both overreported and underreported with use of the CGMS. Thus, adjustment of insulin doses to reduce asymptomatic hypoglycemia identified by the CGMS alone may not be warranted.

Original languageEnglish (US)
Pages (from-to)324-329
Number of pages6
JournalEndocrine Practice
Volume10
Issue number4
DOIs
StatePublished - Jan 1 2004

Fingerprint

Type 1 Diabetes Mellitus
Hypoglycemia
Insulin
Glucose
Hypoglycemic Agents
Control Groups
Physiologic Monitoring
Reading
Hemoglobins

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

What is hypoglycemia in patients with well-controlled type 1 diabetes treated by subcutaneous insulin pump with use of the continuous glucose monitoring system? / Larsen, Jennifer Lynn; Ford, Tim; Lyden, Elizabeth; Colling, Chris; Mack, Lynn R; Lane, James.

In: Endocrine Practice, Vol. 10, No. 4, 01.01.2004, p. 324-329.

Research output: Contribution to journalArticle

@article{f95f73fd7f8d413693196c6ebc56d56c,
title = "What is hypoglycemia in patients with well-controlled type 1 diabetes treated by subcutaneous insulin pump with use of the continuous glucose monitoring system?",
abstract = "Objective: To analyze 72-hour interstitial glucose concentrations measured by a glucose sensor in adult subjects. Methods: We compared glucose levels in 10 patients with type 1 diabetes mellitus (DM-1) and 10 normal control subjects with use of the Medtronic Continuous Glucose Monitoring System (CGMS). Hypoglycemic events identified by the CGMS, the patients, or both were compared in the patients with DM-1. In addition, the results between two glucose sensors placed at similar sites in the same subject were evaluated. Results: Hemoglobin A1c and mean glucose values were higher in the DM-1 group than in the control group (P<0.01), whereas time spent at glucose levels of less than 60, 60 to 79, and 121 to 150 mg/dL were similar between the two study groups. Time spent at glucose levels above 150 mg/dL was greater in the DM-1 group than in the control group (P<0.05). Of the 74 total hypoglycemic events in the patients with DM-1, the sensor and the patient recognized 14{\%}, only the patient recognized 9{\%} (confirmed by readings of <55 mg/dL on a glucose meter), and only the sensor detected 77{\%}. Of note, 41{\%} of the patient-identified symptomatic hypoglycemic events were missed by the CGMS. When one patient with DM-1 and one control subject wore two glucose sensors simultaneously, one and not the other sensor often identified {"}hypoglycemia,{"} and the correlation was only fair to good by intraclass correlation analysis. Conclusion: Many asymptomatic {"}hypoglycemic events{"} identified by the CGMS may not be actual hypoglycemia. Hypoglycemia is both overreported and underreported with use of the CGMS. Thus, adjustment of insulin doses to reduce asymptomatic hypoglycemia identified by the CGMS alone may not be warranted.",
author = "Larsen, {Jennifer Lynn} and Tim Ford and Elizabeth Lyden and Chris Colling and Mack, {Lynn R} and James Lane",
year = "2004",
month = "1",
day = "1",
doi = "10.4158/EP.10.4.324",
language = "English (US)",
volume = "10",
pages = "324--329",
journal = "Endocrine Practice",
issn = "1530-891X",
publisher = "American Association of Clinical Endocrinology",
number = "4",

}

TY - JOUR

T1 - What is hypoglycemia in patients with well-controlled type 1 diabetes treated by subcutaneous insulin pump with use of the continuous glucose monitoring system?

AU - Larsen, Jennifer Lynn

AU - Ford, Tim

AU - Lyden, Elizabeth

AU - Colling, Chris

AU - Mack, Lynn R

AU - Lane, James

PY - 2004/1/1

Y1 - 2004/1/1

N2 - Objective: To analyze 72-hour interstitial glucose concentrations measured by a glucose sensor in adult subjects. Methods: We compared glucose levels in 10 patients with type 1 diabetes mellitus (DM-1) and 10 normal control subjects with use of the Medtronic Continuous Glucose Monitoring System (CGMS). Hypoglycemic events identified by the CGMS, the patients, or both were compared in the patients with DM-1. In addition, the results between two glucose sensors placed at similar sites in the same subject were evaluated. Results: Hemoglobin A1c and mean glucose values were higher in the DM-1 group than in the control group (P<0.01), whereas time spent at glucose levels of less than 60, 60 to 79, and 121 to 150 mg/dL were similar between the two study groups. Time spent at glucose levels above 150 mg/dL was greater in the DM-1 group than in the control group (P<0.05). Of the 74 total hypoglycemic events in the patients with DM-1, the sensor and the patient recognized 14%, only the patient recognized 9% (confirmed by readings of <55 mg/dL on a glucose meter), and only the sensor detected 77%. Of note, 41% of the patient-identified symptomatic hypoglycemic events were missed by the CGMS. When one patient with DM-1 and one control subject wore two glucose sensors simultaneously, one and not the other sensor often identified "hypoglycemia," and the correlation was only fair to good by intraclass correlation analysis. Conclusion: Many asymptomatic "hypoglycemic events" identified by the CGMS may not be actual hypoglycemia. Hypoglycemia is both overreported and underreported with use of the CGMS. Thus, adjustment of insulin doses to reduce asymptomatic hypoglycemia identified by the CGMS alone may not be warranted.

AB - Objective: To analyze 72-hour interstitial glucose concentrations measured by a glucose sensor in adult subjects. Methods: We compared glucose levels in 10 patients with type 1 diabetes mellitus (DM-1) and 10 normal control subjects with use of the Medtronic Continuous Glucose Monitoring System (CGMS). Hypoglycemic events identified by the CGMS, the patients, or both were compared in the patients with DM-1. In addition, the results between two glucose sensors placed at similar sites in the same subject were evaluated. Results: Hemoglobin A1c and mean glucose values were higher in the DM-1 group than in the control group (P<0.01), whereas time spent at glucose levels of less than 60, 60 to 79, and 121 to 150 mg/dL were similar between the two study groups. Time spent at glucose levels above 150 mg/dL was greater in the DM-1 group than in the control group (P<0.05). Of the 74 total hypoglycemic events in the patients with DM-1, the sensor and the patient recognized 14%, only the patient recognized 9% (confirmed by readings of <55 mg/dL on a glucose meter), and only the sensor detected 77%. Of note, 41% of the patient-identified symptomatic hypoglycemic events were missed by the CGMS. When one patient with DM-1 and one control subject wore two glucose sensors simultaneously, one and not the other sensor often identified "hypoglycemia," and the correlation was only fair to good by intraclass correlation analysis. Conclusion: Many asymptomatic "hypoglycemic events" identified by the CGMS may not be actual hypoglycemia. Hypoglycemia is both overreported and underreported with use of the CGMS. Thus, adjustment of insulin doses to reduce asymptomatic hypoglycemia identified by the CGMS alone may not be warranted.

UR - http://www.scopus.com/inward/record.url?scp=17144416158&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17144416158&partnerID=8YFLogxK

U2 - 10.4158/EP.10.4.324

DO - 10.4158/EP.10.4.324

M3 - Article

VL - 10

SP - 324

EP - 329

JO - Endocrine Practice

JF - Endocrine Practice

SN - 1530-891X

IS - 4

ER -